Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Alphagenome-enabled analysis of non-coding regulatory variants underlying rhd expression

Miao Liu, Vahid Mansouri, Jun Liu et al. Nov 03, 2025 pp. 4356-4356 10.1182/blood-2025-4356

Abstract Introduction RhD is a critical blood group antigen associated with hemolytic transfusion reactions and fetal/newborn disease. While...

The importance of MRI in diagnostic workup of smoldering multiple myeloma

Roshani Patel, Baris Turkbey, Peter Choyke et al. Nov 03, 2025 pp. 5767-5767 10.1182/blood-2025-5767

Abstract Background In 2014, the International Myeloma Working Group (IMWG) revised the diagnostic criteria for multiple myeloma (MM), incor...

Effect of plasmapheresis on mortality and length of stay in hospitalized patients with thrombotic thrombocytopenic purpura

Aman Ullah, Abdul Mateen, Najam Gohar et al. Nov 03, 2025 pp. 4888-4888 10.1182/blood-2025-4888

Abstract Background Thrombotic Thrombocytopenic Purpura (TTP) is a rare and serious thrombotic microangiopathy that's defined by the confirm...

Optimizing high-dose methotrexate treatment regimens to improve exposure and mitigate toxicity in infant patients with acute lymphoblastic leukemia

Zachary Taylor, Erin Breese, Kelly Faulk et al. Nov 03, 2025 pp. 4531-4531 10.1182/blood-2025-4531

Abstract Introduction: High-dose methotrexate (HDMTX) is a key component of therapy for high risk acute lymphoblastic leukemia (ALL). Typica...

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

Devendra Hiwase, Steven Tessier, Kevin Hung et al. Nov 03, 2025 pp. 2087-2087 10.1182/blood-2025-2087

Abstract Background: TP53-mutated myeloid neoplasms (MNs) represent one of the most lethal subgroups of blood cancers. The World Health Orga...

The charlson comorbidity index as a predictor of survival in peripheral T-cell lymphoma: A multicenter analysis from the gifu hematology study group

Naoki Hayase, Nobuhiko Nakamura, Yuto Kaneda et al. Nov 03, 2025 pp. 1863-1863 10.1182/blood-2025-1863

Abstract Background: Peripheral T-cell lymphoma (PTCL) is one of the most aggressive subtypes of non-Hodgkin's lymphoma, with a 5-year survi...

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan et al. Nov 03, 2025 pp. 1746-1746 10.1182/blood-2025-1746

Abstract Introduction: Although CD19-targeted chimeric antigen receptor T-cell (CD19-CAR-T) therapy is highly effective in relapsed or refra...

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

Adaia Albasanz Puig, Víctor Navarro Garces, Carolina Martinez Gomez et al. Nov 03, 2025 pp. 782-782 10.1182/blood-2025-782

Abstract INTRODUCTION: T-cell redirecting strategies (TRS), including chimeric antigen receptor (CAR) T cells and bispecific antibodies (BsA...

Zanubrutinib maintenance post-autologous stem cell transplantation in Mantle Cell Lymphoma: A prospective multicenter Phase II trial

Wenli Zhang, Zhen Li, Ruirui Gui et al. Nov 03, 2025 pp. 7106-7106 10.1182/blood-2025-7106

Abstract Introduction Autologous stem cell transplantation (ASCT) is a potent treatment to improve the prognosis of mantle cell lymphoma (MC...

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

Tracy Chow, Nicholas Stong, Keyur Desai et al. Nov 03, 2025 pp. 5697-5697 10.1182/blood-2025-5697

Abstract Introduction: Mezigdomide (MEZI) is an oral CELMoD™ agent that induces rapid and potent degradation of lkaros and Aiolos. Reduction...

Interim analysis of a Phase I/II study of tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma

Michael Randall, Andreas Rauschecker, Lingjing Chen et al. Nov 03, 2025 pp. 1969-1969 10.1182/blood-2025-1969

Abstract Introduction The development of novel, effective and well-tolerated biological strategies to treat primary and secondary CNS lympho...

Real-world survival of IDH-mutant patients in China before IDH-inhibitor era: A multicenter retrospective study from anhui cooperative hematology group(ACHG)

Enbo Chen, Xuemei Wu, Yuanfeng Wei et al. Nov 03, 2025 pp. 3389-3389 10.1182/blood-2025-3389

Abstract The impact of IDH mutations on the survival of AML patients is unclear. Since the VIALE-A study shows improved survival for patient...

Impact of pomalidomide-containing induction chemotherapy on hematopoietic stem cell mobilization in multiple myeloma: A retrospective cohort study

Lifen Kuang, Juan Li Nov 03, 2025 pp. 7545-7545 10.1182/blood-2025-7545

Abstract Introduction Pomalidomide (POM), a potent immunomodulatory agent, is increasingly used in multiple myeloma (MM). Preclinical data s...

Sepsis in Acute Myeloid Leukemia (AML) patients: A 407,095-patient national inpatient sample study (2016-2022)

Aman Ullah, Najam Gohar, Muhammad Zahid et al. Nov 03, 2025 pp. 6922-6922 10.1182/blood-2025-6922

Abstract Introduction Sepsis is a leading cause of morbidity and mortality in patients with cancer, but its impact in acute myeloid leukemia...

Factor XI haploinsufficiency is protective against venous thromboembolism and myocardial infarction in population-scale multidimensional datasets

Alfonso Rodriguez Espada, Amelia Haj, Sean Jurgens et al. Nov 03, 2025 pp. 1281-1281 10.1182/blood-2025-1281

Abstract Background: Coagulation factor XI (FXI, F11) inhibitors are a novel antithrombotic strategy that may carry a lower risk of spontane...

HMGA1 chromatin regulators drive transcriptional networks involved in megakaryocyte expansion, fibrosis, and sensitivity to interferon signaling in JAK2-V617F MPN

Linda Resar, Zanshé Thompson, Li Luo et al. Nov 03, 2025 pp. 7285-7285 10.1182/blood-2025-7285

Abstract Introduction: Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell (HSC) disorders with an increased risk of trans...

Enhancing hemostasis in glanzmann thrombasthenia via protein S inhibition

Rim Diab, Tanja Knopp, Mathieu Fiore et al. Nov 03, 2025 pp. 3025-3025 10.1182/blood-2025-3025

Abstract Introduction: Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding disorder caused by a deficiency of the platelet...

CAR-T cell therapy in multiple myeloma in a front-line setting: A systematic review and meta-analysis

Hafiz Muhammad Hannan Javed, Hafsa Shahid, Farooq Ashraf et al. Nov 03, 2025 pp. 7605-7605 10.1182/blood-2025-7605

Abstract Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy targeting the B-cell maturation antigen (BCMA) has consistently prod...

Talquetamab in Relapsed/Refractory multiple myeloma with renal impairment: A quaternary cancer center experience

Hossam M. Ali, Sandra Mazzoni, Utkarsh Goel et al. Nov 03, 2025 pp. 6367-6367 10.1182/blood-2025-6367

Abstract Introduction Patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment (RI) represent a high-risk group freque...

A case series on cutaneous reactions to ivig

Michel Lu, Kate O'Connor, Jacinta Perram Nov 03, 2025 pp. 4920-4920 10.1182/blood-2025-4920

Abstract Intravenous immunoglobulin (IVIg) is increasingly utilised to treat a wide spectrum of indications. While generally well-tolerated,...

Development of whole blood viscosity measurements under hypoxia for use in sickle cell disease

Mary Aliche, Ashwin Patel, Vivien Sheehan Nov 03, 2025 pp. 6120-6120 10.1182/blood-2025-6120

Abstract Introduction: Sickle cell disease (SCD) is an inherited blood disorder caused by an amino acid change that prod...

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Inhye Ahn, Zunqiu Wang, Svitlana Tyekucheva et al. Nov 03, 2025 pp. 2113-2113 10.1182/blood-2025-2113

Abstract Background: Critical barriers to precision medicine in CLL include molecular heterogeneity of the disease and limited availability...

A phase I study of venetoclax in combination with multiagent cytotoxic chemotherapy for children and adolescents with relapsed or refractory acute lymphoblastic leukemia or mixed phenotype acute leukemia: Results of the dose determination cohort

Melissa Burns, Yael Flamand, Jessica Pollard et al. Nov 03, 2025 pp. 5125-5125 10.1182/blood-2025-5125

Abstract Background Relapse is the most common cause of treatment failure for children and adolescents with acute lymphoblastic leukemia (AL...

Acute myeloid leukemias with UBTF tandem duplications respond to combined BCL-2 and RNA polymerase I inhibition with increased stemness and a quiescent-like state

Patrick Stelmach, Nesrine Aroua, Dawn Lin et al. Nov 03, 2025 pp. 342-342 10.1182/blood-2025-342

Abstract Acute myeloid leukemia (AML) with tandem duplications in the upstream binding transcription factor gene (UBTF-TD) has recently been...

Age-specific impact of apoptosis gene expression and recurrent mutations on remission and survival in AML: A machine learning-based analysis

Mobina Shrestha, Salina Dahal, Sabin Karki Nov 03, 2025 pp. 7031-7031 10.1182/blood-2025-7031

Abstract Patient's age remains one of the most important prognostic factors in acute myeloid leukemia (AML), but the extent to which age inf...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page